Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence

Julia A Belk1, Winnie Yao2, Nghi Ly2

  • 1Department of Computer Science, Stanford University, Stanford, CA 94305, USA; Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA 94158, USA.

Cancer Cell
|June 24, 2022
PubMed

Insights

T cell exhaustion hinders cancer immunity. Epigenetic regulators, like the BAF complex member Arid1a, were identified to improve T cell persistence and antitumor responses in tumors.

Area of Science:

  • Immunology
  • Epigenetics
  • Cancer Biology

Background:

  • T cell exhaustion is a critical barrier to effective antitumor immunity in cancer.
  • The molecular mechanisms driving T cell exhaustion are not fully understood, limiting therapeutic strategies.

Purpose of the Study:

  • To systematically identify genetic regulators of T cell exhaustion using genome-wide CRISPR screens.
  • To investigate the role of chromatin remodeling complexes in T cell exhaustion and antitumor immunity.

Main Methods:

  • Genome-wide CRISPR-Cas9 screens in chronic stimulation assays and in vivo tumor models (murine and human).
  • Perturb-seq analysis to determine transcriptional roles of chromatin remodeling complexes.
  • Assessment of T cell persistence, effector programs, exhaustion-related gene expression, and chromatin accessibility.

Main Results:

  • Epigenetic factors, including the INO80 and BAF chromatin remodeling complexes, were identified as key regulators of T cell exhaustion.
  • Perturbation of INO80 and BAF complexes enhanced T cell persistence within tumors.
  • Depletion of BAF complex members, such as Arid1a, maintained T cell effector programs, downregulated exhaustion markers, and improved antitumor immunity by limiting epigenetic changes associated with exhaustion.

Conclusions:

  • This study provides a comprehensive genetic atlas of T cell exhaustion regulators.
  • Targeting epigenetic modifiers, specifically the BAF complex, represents a promising strategy to enhance T cell function in cancer immunotherapy.